Resource Center

www.lls.org/resourcecenter

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:

promo_left_donate

December 1, 2011 - Making Cancer Treatment Decisions

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: December 1, 2011
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
Access: Program Slides
Listen: Presentation | Q&A Session
Read: Transcript

Topics Covered

  • Questions patients need to ask to make informed treatment decisions
  • Benefit-and-risk issues for standard treatments and clinical trials
  • Reasons for a patient to consider a clinical trial
  • How clinical trials are designed and monitored
  • Financial considerations related to cancer treatment

Speakers

Gail J. Roboz, MD
Director, Leukemia Program
Associate Professor of Medicine
Weill Medical College of Cornell University
New York-Presbyterian Hospital
New York, NY

Beth Patterson
President, Mission Delivery
Patient Advocate Foundation
Hampton, VA

Questions Asked by the Cancer Community

  • When a patient is given a choice between two different treatment options, how is he or she supposed to decide which one will be the most beneficial?
  • What are some of the questions to ask that will help in making a decision about treatment?
  • Before beginning a treatment, what should be included in an informed consent?
  • Are there clinical trials for relapsed conditions?
  • When one goes into a clinical trial with a center of excellence, should the center be providing an ombudsman or patient advocate?
  • Does Medicaid in all states cover clinical trials?
  • Does the pre-existing condition insurance cover clinical trials?
  • Should one start with an aggressive protocol of treatment or is it better to start out conservatively and then move to a more aggressive treatment?
  • In a clinical trial, are there pharmaceutical companies that do not pay for the cost of their drugs?
  • How is someone selected for a clinical trial?
  • Would a previous diagnosis of hemolytic anemia, which is now under control, be an underlying concern taken into consideration before starting treatment with standard therapy?
  • Once a clinical trial is completed, does the doctor, facility or sponsoring company have a requirement to inform participants of the outcome?
  • Will NCI help patients who need to travel to a hospital for clinical-trial participation outside of their clinical center in Maryland?
  • Does it cost money to utilize services or assistance provided by the Patient Advocate Foundation?

Sponsors and Supporters

This program was sponsored by The Leukemia & Lymphoma Society and supported by grants from Celgene Corporation and Millennium Pharmaceuticals, Inc.

last updated on Friday, April 19, 2013
btn_sharethis

Get Information
& Support

Contact an Information Specialist.